Canlyniadau Chwilio - Huitema, Alwin D R

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels gan Groenland, Stefanie L., Katz, Daniela, Huitema, Alwin D. R., Steeghs, Neeltje

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter] gan Hendrikx, Jeroen J M A, Beijnen, Jos H, Huitema, Alwin D R

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Exposure‐response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components gan Bastida, Carla, Soy, Dolors, Ruiz‐Esquide, Virginia, Sanmartí, Raimon, Huitema, Alwin D.R.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis gan Dorlo, Thomas P. C., Huitema, Alwin D. R., Beijnen, Jos H., de Vries, Peter J.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice gan Simeoli, Raffaele, Dorlo, Thomas P. C., Hanff, Lidwien M., Huitema, Alwin D. R., Dreesen, Erwin

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses gan Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152) gan Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Proton Pump Inhibitor Prophylaxis After Gastric Bypass Does Not Cause Hypomagnesemia gan Boerlage, Thomas C. C., van Hees, Charlotte L. E., Huitema, Alwin D. R., Lauw, Fanny N.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing gan Verheijen, Remy B., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R., Steeghs, Neeltje

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes gan van Eijk, Maarten, Boosman, René J., Schinkel, Alfred H., Huitema, Alwin D. R., Beijnen, Jos H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS gan de Jong, Karen A.M., Rosing, Hilde, Vermunt, Marit, Huitema, Alwin D.R., Beijnen, Jos H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review gan Verrest, Luka, Wilthagen, Erica A., Beijnen, Jos H., Huitema, Alwin D. R., Dorlo, Thomas P. C.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Correction to: Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review gan Verrest, Luka, Wilthagen, Erica A., Beijnen, Jos H., Huitema, Alwin D. R., Dorlo, Thomas P. C.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin gan Zandvliet, Anthe S, Schellens, Jan H M, Dittrich, Christian, Wanders, Jantien, Beijnen, Jos H, Huitema, Alwin D R

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2′,2′‐difluorodeoxyuridine and their nucleotides gan Derissen, Ellen J. B., Huitema, Alwin D. R., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model gan ter Heine, Rob, Kane, Sean P., Huitema, Alwin D.R., Krasowski, Matthew D., van Maarseveen, Erik M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs gan Molenaar-Kuijsten, Laura, Van Balen, Dorieke E. M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D. R.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa gan Ekhart, Corine, Doodeman, Valerie D, Rodenhuis, Sjoerd, Smits, Paul H M, Beijnen, Jos H, Huitema, Alwin D R

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents gan Zandvliet, Anthe S., Karlsson, Mats O., Schellens, Jan H. M., Copalu, William, Beijnen, Jos H., Huitema, Alwin D. R.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer gan Koolen, Stijn L W, Oostendorp, Roos L, Beijnen, Jos H, Schellens, Jan H M, Huitema, Alwin D R

Cael y testun llawn Cael y testun llawn Cael y testun llawn